NOV Inc. Stock
There is an upward development for NOV Inc. compared to yesterday, with an increase of €0.20 (1.400%).
Currently there is a rather positive sentiment for NOV Inc. with 15 Buy predictions and 6 Sell predictions.
With a target price of 15 € there is a slightly positive potential of 6.19% for NOV Inc. compared to the current price of 14.13 €.
Our community identified positive and negative aspects for NOV Inc. stock for the coming years. 1 users see the criterium "Balance Sheet Risk" as a plus for the NOV Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of NOV Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of NOV Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| NOV Inc. | 1.400% | 1.692% | 5.489% | -0.563% | 2.133% | -26.047% | 24.340% |
| Cimc Enric Holdings Inc. | 2.410% | -2.299% | 5.590% | 2.410% | 1.190% | -4.387% | 97.674% |
| John Wood Group | -0.400% | -5.407% | 2.985% | -69.314% | -67.316% | -83.765% | -92.677% |
| Core Laboratories Inc. | -2.800% | -3.472% | 6.107% | -24.865% | -13.125% | -23.836% | -41.597% |
Comments
NOV (NYSE:NOV) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Show more
Ratings data for NOV provided by MarketBeat
NOV (NYSE:NOV) was given a new $19.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
Show more
Ratings data for NOV provided by MarketBeat
NOV (NYSE:NOV) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $19.00 price target on the stock.
Show more
Ratings data for NOV provided by MarketBeat